Steve Flanagan, MD
Physical Medicine and Rehabilitation · New York, NYNPI 1962470815
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Avanir Pharmaceuticals, Inc. accounts for 77.3% of it on its own, with 2 other manufacturers making up the rest.
Across 24 payments — averaging $83.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$2K
- Merz North America, Inc.$422
- Medtronic$35
Across 7 payments — averaging $4877.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$22K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$13K
What the payments were for
- Travel & lodging$1,07253%
- Food & beverage$48724%
- Education$45623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 16 | $1,558 |
| Merz North America, Inc. | 6 | $422 |
| Medtronic(2 entities) | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$246
How this compares
$2,015 in reported general payments places this provider in the 85th percentile of 872 physical medicine and rehabilitation providers in New York.
See all physical medicine and rehabilitation providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate ErMethylphenidate Hcl | 20 | $1,359 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 28 | $552 |
| Chlorpromazine Hcl | 12 | $399 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $316 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $316 |
| Buspirone Hcl | 12 | $181 |
| Methylphenidate Hcl | 22 | $172 |
Paid to pharmacies, not to this prescriber.
Other physical medicine and rehabilitation in New York
- Heidi FuscoNew York$153K
- Michael OdellNew York$67K
- Craig AntellNew York$65K
- Michael StubblefieldNew York$53K
- Heakyung KimNew York$53K
- Russell SilverNew York$34K
- Julia IafrateNew York$32K
- Neil JaseyNew York$29K
- Christian CustodioNew York$19K
- Karan JoharNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.